Executive Vice President, AstraZeneca
Dr. Menelas Pangalos, Ph.D. is Executive Vice President, Innovative Medicines and leads AstraZeneca’s small molecule discovery research and early development activities. A member of the company’s Senior Executive team, Menelas has overall responsibility for the company’s small molecule discovery research and early development activities. Menelas came to AstraZeneca from Pfizer, where he was appointed Senior Vice President and Chief Scientific Officer of Neuroscience Research, following the acquisition of Wyeth. Menelas completed his undergraduate degree in Biochemistry at Imperial College of Science and Technology and earned a Ph.D. in Neurochemistry from the Institute of Neurology, both at the University of London. He is a visiting professor at King’s College London’s Wolfson Centre for Age-Related Diseases and is on the Innovation Board for the Association of the British Pharmaceutical Industry, the Enhancing Value Task Force for CIHE-UK, the Board of the British Pharmaceutical Group and the Prime Minister’s Research Champion Group for Dementia. He is a Fellow of the Society for Biology, a Member of the American Society of Neuroscience and the British Pharmacology Society and an Associate of the Royal College of Science. Menelas has been appointed to a four-year term on the UK Medical Research Council (MRC).